A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom.
Rallybio, focused on rare diseases, has not yet publicly identified any drug candidates it’s pursuing, but that hasn’t stopped it from raising $37 million in venture funding.
Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.